BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1227 related articles for article (PubMed ID: 34058265)

  • 21. Molecular Insights of SARS-CoV-2 Infection and Molecular Treatments.
    Abdurrahman L; Fang X; Zhang Y
    Curr Mol Med; 2022; 22(7):621-639. PubMed ID: 34645374
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Current Status and Challenges in the Development of Vaccines and Drugs against Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-CoV-2).
    Beeraka NM; Tulimilli SV; Karnik M; Sadhu SP; Pragada RR; Aliev G; Madhunapantula SV
    Biomed Res Int; 2021; 2021():8160860. PubMed ID: 34159203
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diverse Humoral Immune Responses in Younger and Older Adult COVID-19 Patients.
    Sasson JM; Campo JJ; Carpenter RM; Young MK; Randall AZ; Trappl-Kimmons K; Oberai A; Hung C; Edgar J; Teng AA; Pablo JV; Liang X; Yee A; Petri WA; Camerini D
    mBio; 2021 Jun; 12(3):e0122921. PubMed ID: 34182775
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long Noncoding RNAs as Emerging Regulators of COVID-19.
    Yang Q; Lin F; Wang Y; Zeng M; Luo M
    Front Immunol; 2021; 12():700184. PubMed ID: 34408749
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential core genes associated with COVID-19 identified via weighted gene co-expression network analysis.
    Wu C; Wu Z; Chen Y; Huang X; Tian B
    Swiss Med Wkly; 2022 Nov; 152():40033. PubMed ID: 36509426
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential gene expression profiling reveals potential biomarkers and pharmacological compounds against SARS-CoV-2: Insights from machine learning and bioinformatics approaches.
    Hoque MN; Sarkar MMH; Khan MA; Hossain MA; Hasan MI; Rahman MH; Habib MA; Akter S; Banu TA; Goswami B; Jahan I; Nafisa T; Molla MMA; Soliman ME; Araf Y; Khan MS; Zheng C; Islam T
    Front Immunol; 2022; 13():918692. PubMed ID: 36059456
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Large-Scale Structure-Based Screening of Potential T Cell Cross-Reactivities Involving Peptide-Targets From BCG Vaccine and SARS-CoV-2.
    Tarabini RF; Rigo MM; Faustino Fonseca A; Rubin F; Bellé R; Kavraki LE; Ferreto TC; Amaral Antunes D; de Souza APD
    Front Immunol; 2021; 12():812176. PubMed ID: 35095907
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantitative Insight into Immunopathology of SARS-CoV-2 Infection.
    Soni B; Kabra R; Singh S
    J Interferon Cytokine Res; 2021 Jul; 41(7):244-257. PubMed ID: 34280026
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential interferon-α subtype induced immune signatures are associated with suppression of SARS-CoV-2 infection.
    Schuhenn J; Meister TL; Todt D; Bracht T; Schork K; Billaud JN; Elsner C; Heinen N; Karakoese Z; Haid S; Kumar S; Brunotte L; Eisenacher M; Di Y; Lew J; Falzarano D; Chen J; Yuan Z; Pietschmann T; Wiegmann B; Uebner H; Taube C; Le-Trilling VTK; Trilling M; Krawczyk A; Ludwig S; Sitek B; Steinmann E; Dittmer U; Lavender KJ; Sutter K; Pfaender S
    Proc Natl Acad Sci U S A; 2022 Feb; 119(8):. PubMed ID: 35131898
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dendritic cells in COVID-19 immunopathogenesis: insights for a possible role in determining disease outcome.
    Borges RC; Hohmann MS; Borghi SM
    Int Rev Immunol; 2021; 40(1-2):108-125. PubMed ID: 33191813
    [TBL] [Abstract][Full Text] [Related]  

  • 32. T-cell responses and therapies against SARS-CoV-2 infection.
    Toor SM; Saleh R; Sasidharan Nair V; Taha RZ; Elkord E
    Immunology; 2021 Jan; 162(1):30-43. PubMed ID: 32935333
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?
    Lu L; Zhang H; Zhan M; Jiang J; Yin H; Dauphars DJ; Li SY; Li Y; He YW
    Sci China Life Sci; 2020 Dec; 63(12):1833-1849. PubMed ID: 33355886
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
    Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
    mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination.
    Zheng C; Kar I; Chen CK; Sau C; Woodson S; Serra A; Abboud H
    CNS Drugs; 2020 Sep; 34(9):879-896. PubMed ID: 32780300
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The emergence of COVID-19 as a global pandemic: Understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2.
    Muralidar S; Ambi SV; Sekaran S; Krishnan UM
    Biochimie; 2020 Dec; 179():85-100. PubMed ID: 32971147
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune profiling of COVID-19: preliminary findings and implications for the pandemic.
    Maecker HT
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963016
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunomodulatory agents as potential therapeutic or preventive strategies for COVID-19.
    Gaziano R; Pistoia ES; Campione E; Fontana C; Marino D; Favaro M; Pica F; Di Francesco P
    Eur Rev Med Pharmacol Sci; 2021 Jun; 25(11):4174-4184. PubMed ID: 34156699
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Innate immunity in COVID-19: Drivers of pathogenesis and potential therapeutic targets.
    Ruenjaiman V; Hirankarn N; Palaga T
    Asian Pac J Allergy Immunol; 2021 Jun; 39(2):69-77. PubMed ID: 34174806
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biomarkers and Immune Repertoire Metrics Identified by Peripheral Blood Transcriptomic Sequencing Reveal the Pathogenesis of COVID-19.
    Liu Y; Wu Y; Liu B; Zhang Y; San D; Chen Y; Zhou Y; Yu L; Zeng H; Zhou Y; Zhou F; Yang H; Yin L; Huang Y
    Front Immunol; 2021; 12():677025. PubMed ID: 34504487
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 62.